Literature DB >> 12034807

First-line therapy with temozolomide induces regression of primary CNS lymphoma.

U Herrlinger1, W Küker, M Platten, J Dichgans, M Weller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12034807     DOI： 10.1212/wnl.58.10.1573

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  13 in total

1.  Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.

Authors:  Keishi Makino; Hideo Nakamura; Taku-Ichiro Hide; Jun-Ichi Kuratsu
Journal:  J Neurooncol       Date:  2011-07-01       Impact factor: 4.130

2.  O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.

Authors:  Jun-Ichi Adachi; Kazuhiko Mishima; Kenji Wakiya; Tomonari Suzuki; Kohei Fukuoka; Takaaki Yanagisawa; Masao Matsutani; Atsushi Sasaki; Ryo Nishikawa
Journal:  J Neurooncol       Date:  2011-10-04       Impact factor: 4.130

3.  High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).

Authors:  Maher Salamoon; Taisir Hussein; Mazen Kenj; Marrouan Bachour
Journal:  Med Oncol       Date:  2013-08-20       Impact factor: 3.064

4.  Successful Use of High Dose Methotrexate in Treatment of Primary CNS Lymphoma Patients Without Access to Serum Methotrexate Levels Monitoring: Challenges and Outcome.

Authors:  Charanpreet Singh; Arihant Jain; Aastha Takkar; Aniruddha Agarwal; Manish Rohilla; Deepesh Lad; Alka Khadwal; Rajender Basher; B D Radotra; Amanjit Bal; Ashim Das; Vishali Gupta; Vivek Lal; Subhash Varma; Pankaj Malhotra; Gaurav Prakash
Journal:  Indian J Hematol Blood Transfus       Date:  2021-05-12       Impact factor: 0.900

5.  Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.

Authors:  Cigall Kadoch; Eduard B Dinca; Ramona Voicu; Lingjing Chen; Diana Nguyen; Seema Parikh; Juliana Karrim; Marc A Shuman; Clifford A Lowell; Patrick A Treseler; C David James; James L Rubenstein
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

6.  Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.

Authors:  Antonio M P Omuro; Luc Taillandier; Olivier Chinot; Charlotte Carnin; Maryline Barrie; Khe Hoang-Xuan
Journal:  J Neurooncol       Date:  2007-09-21       Impact factor: 4.130

7.  O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Authors:  Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jennifer A Quinn; Alan D Austin; James E Herndon; Roger E McLendon; Henry S Friedman
Journal:  J Neurooncol       Date:  2013-05-18       Impact factor: 4.130

8.  Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status.

Authors:  Delia Kurzwelly; Martin Glas; Patrick Roth; Elke Weimann; Hanns Lohner; Andreas Waha; Martin Schabet; Guido Reifenberger; Michael Weller; Ulrich Herrlinger
Journal:  J Neurooncol       Date:  2009-10-20       Impact factor: 4.130

9.  Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.

Authors:  Jon Glass; Minhee Won; Christopher J Schultz; Daniel Brat; Nancy L Bartlett; John H Suh; Maria Werner-Wasik; Barbara Jean Fisher; Marcia K Liepman; Mark Augspurger; Felix Bokstein; Joseph A Bovi; Matthew C Solhjem; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2016-03-28       Impact factor: 44.544

10.  Primary central nervous system lymphoma.

Authors:  Hendrik Pels; Uwe Schlegel
Journal:  Curr Treat Options Neurol       Date:  2006-07       Impact factor: 3.972
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.